Skip to content

Robin Carhart-Harris

Imperial College London, Multidisciplinary Association for Psychedelic Studies

312 papers in the library · 30,055 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.

Psychological Medicine 2024 Brandon Weiss, Induni Ginige, Lu Shannon et al. 38 citations

Psilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and can be used to probe the nature of PT's therapeutic action. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, over a core 6-week trial...

Brain dynamics predictive of response to psilocybin for treatment-resistant depression.

Brain Communications 2024 Jakub Vohryzek, Joana Cabral, Louis-David Lord et al. 33 citations

Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here, we leveraged the differential outcome in responders and non-responders to psilocybin (10 and 25 mg, 7 days apart) therapy for depression-to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used large-scale brain...

DOI: 10.1093/braincomms/fcae049 (opens in new tab) Full text (opens in new tab) Large-scale brain modelling Psilocybin treatment Psilocybin therapy Neuroscience research +3

A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex.

Brain 2024 Andrea I. Luppi, Manesh Girn, Fernando E. Rosas et al. 25 citations

Integrating independent but converging lines of research on brain function and neurodevelopment across scales, this article proposes that serotonin 2A receptor (5-HT2AR) signalling is an evolutionary and developmental driver and potent modulator of the macroscale functional organization of the human cerebral cortex. A wealth of evidence indicates that the anatomical and functional organization...

DOI: 10.1093/brain/awad311 (opens in new tab) Evolutionary expansion Uniquely human-expanded areas Transmodal cortex Sophisticated functioning +7

Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects

Neuroscience of Consciousness 2024 Charlotte Martial, Robin Carhart-Harris, Christopher Timmermann 9 citations

Abstract Mystical-like states of consciousness may arise through means such as psychedelic substances, but may also occur unexpectedly during near-death experiences (NDEs). So far, research studies comparing experiences induced by serotonergic psychedelics and NDEs, along with their enduring effects, have employed between-subject designs, limiting direct comparisons. We present results from an...

DOI: 10.1093/nc/niae033 (opens in new tab) Full text (opens in new tab) Consciousness studies phenomenology Altered states Awareness Impact +8

Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.

Frontiers in Psychiatry 2024 Matthew X. Lowe, Hannes Kettner, Del R. P. Jolly et al. 9 citations

Refugees and immigrants can experience complex stressors from the process of immigration that can have lasting and severe long-term mental health consequences. Experiences after ayahuasca ingestion are shown to produce positive effects on psychological wellbeing and mental health, including anecdotal reports of improved symptoms of trauma and related disorders. However, data on the longitudinal...

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations

5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...

DOI: 10.1007/s00213-023-06517-1 (opens in new tab) Full text (opens in new tab) 5-ht1a receptors Flashbacks Seizures Psychedelics hallucinogens +7

Statistical diversity distinguishes global states of consciousness

bioRxiv December 7, 2023 Joseph Starkey, Robin Carhart-Harris, Andrea Pigorini et al. preprint

Abstract Application of complexity measures to neurophysiological time series has seen increased use in recent years to identify neural correlates of global states of consciousness. Lempel-Ziv complexity is currently the de-facto complexity measure used in these investigations. However, by simply counting the number of patterns, this measure theoretically takes its maximum value for data that...

DOI: 10.1101/2023.12.05.570101 (opens in new tab) Consciousness states States of awareness Levels of consciousness Conscious states +19

LSD-induced changes in the functional connectivity of distinct thalamic nuclei.

Neuroimage December 1, 2023 Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al. 27 citations

The role of the thalamus in mediating the effects of lysergic acid diethylamide (LSD) was recently proposed in a model of communication and corroborated by imaging studies. However, a detailed analysis of LSD effects on nuclei-resolved thalamocortical connectivity is still missing. Here, in a group of healthy volunteers, we evaluated whether LSD intake alters the thalamocortical coupling in a...

The entropic heart: Tracking the psychedelic state via heart rate dynamics

bioRxiv (Cold Spring Harbor Laboratory) November 9, 2023 Fernando E. Rosas, Pedro A. M. Mediano, Christopher Timmermann et al. 14 citations preprint

A growing body of work shows that autonomic signals provide a privileged evidence-stream to capture various aspects of subjective and neural states. This work investigates the potential for autonomic markers to track the effects of psychedelics — potent psychoactive drugs with important scientific and clinical value. For this purpose, we introduce a novel Bayesian framework to estimate the...

DOI: 10.1101/2023.11.07.566008 (opens in new tab) Full text (opens in new tab) Psilocybin Heart rate variability Artificial intelligence Hallucinogen +1

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans.

Psychological Medicine October 1, 2023 Jonathan W. Kanen, Qiang Luo, Mojtaba Rostami Kandroodi et al. 44 citations

The non-selective serotonin 2A (5-HT2A) receptor agonist lysergic acid diethylamide (LSD) holds promise as a treatment for some psychiatric disorders. Psychedelic drugs such as LSD have been suggested to have therapeutic actions through their effects on learning. The behavioural effects of LSD in humans, however, remain incompletely understood. Here we examined how LSD affects probabilistic...

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.

CPT: Pharmacometrics & Systems Pharmacology October 1, 2023 Emma Eckernäs, Jeroen Koomen, Christopher Timmermann et al. 1 citation

N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic...

DOI: 10.1002/psp4.13037 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy DMT-Research Clinical-protocols Pharmacology +1

Case analysis of long-term negative psychological responses to psychedelics

Scientific Reports September 25, 2023 Rebecka Bremler, Nancy Katati, Parvinder Shergill et al. 102 citations

Abstract Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes. The present study was motivated by a desire to address this alleged bias by intentionally focusing exclusively on negative outcomes,...

DOI: 10.1038/s41598-023-41145-x (opens in new tab) Full text (opens in new tab) Thematic analysis Qualitative research Salient Clinical psychology

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports August 22, 2023 Hannes Kettner, Stephen Ross, Richard J. Zeifman et al. 31 citations

Abstract Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging...

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing

Psychopharmacology August 22, 2023 Robert F. Dougherty, Patrick Clarke, Merve Atli et al. 21 citations

Abstract Rationale Therapeutic administration of psychedelics has shown significant potential in historical accounts and recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilocybin, in participants with...

Harmonic decomposition of spacetime (HADES) framework characterises the spacetime hierarchy of the DMT brain state

bioRxiv August 21, 2023 Jakub Vohryzek, Joana Cabral, Christopher Timmermann et al. 7 citations preprint

Abstract The human brain is a complex system, whose activity exhibits flexible and continuous reorganisation across space and time. The decomposition of whole-brain recordings into harmonic modes has revealed a repertoire of gradient-like activity patterns associated with distinct brain functions. However, the way these activity patterns are expressed over time with their changes in various...

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.

Journal of Affective Disorders August 1, 2023 Richard J. Zeifman, Anne C Wagner, Candice M Monson et al. 56 citations

Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...

The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.

Scientific Reports July 26, 2023 Balázs Szigeti, David Nutt, Robin Carhart-Harris et al. 33 citations

In medical trials, 'blinding' ensures the equal distribution of expectancy effects between treatment arms in theory; however, blinding often fails in practice. We use computational modelling to show how weak blinding, combined with positive treatment expectancy, can lead to an uneven distribution of expectancy effects. We call this 'activated expectancy bias' (AEB) and show that AEB can inflate...

DOI: 10.1038/s41598-023-34938-7 (opens in new tab) Placebo effect Expectation bias Mind-body connection Psychological impact +14

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

Psychiatry Research July 23, 2023 Otto Simonsson, Per Carlbring, Robin Carhart-Harris et al. 24 citations

We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using...

DOI: 10.1016/j.psychres.2023.115349 (opens in new tab) Meta-analysis Psilocybin therapy Clinical depression treatment Psychedelic medicine +2

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM

Psychological Medicine July 19, 2023 Brandon Weiss, Induni Ginige, Lu Shannon et al. 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.

Increased low-frequency brain responses to music after psilocybin therapy for depression.

Journal of Affective Disorders July 15, 2023 Matthew B. Wall, Cynthia Lam, Natalie Ertl et al. 36 citations

Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...

Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging July 1, 2023 Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al. 18 citations

Lysergic acid diethylamide (LSD) is an atypical psychedelic compound that exerts its effects through pleiotropic actions, mainly involving 1A/2A serotoninergic (5-HT) receptor subtypes. However, the mechanisms by which LSD promotes a reorganization of the brain's functional activity and connectivity are still partially unknown. Our study analyzed resting-state functional magnetic resonance...

In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape

Science Advances June 14, 2023 Leor Roseman, Christopher Timmermann, Daniel Golkowski et al. 65 citations

To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically induced macroscale functional reorganization, by relating the regional distribution of 19 neurotransmitter receptors and transporters...

DOI: 10.1126/sciadv.adf8332 (opens in new tab) Pharmacology Neurotransmitter receptor Human brain

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience

bioRxiv (Cold Spring Harbor Laboratory) May 12, 2023 S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 18 citations preprint

Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...

A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression

Journal of Psychopharmacology April 25, 2023 Brandon Weiss, David Erritzøe, Bruna Giribaldi et al. 24 citations

Background: In a recent clinical trial examining the comparative efficacy of psilocybin therapy (PT) versus escitalopram treatment (ET) for major depressive disorder, 14 of 16 major efficacy outcome measures yielded results that favored PT, but the Quick Inventory of Depressive Symptomatology, Self-Report, 16 items (QIDS-SR 16 ) did not. Aims: The present study aims to (1) rationally and...

DOI: 10.1177/02698811231167848 (opens in new tab) Clinical trial Qids Depression measurement Escitalopram +5

A whole-brain model of the neural entropy increase elicited by psychedelic drugs.

Scientific Reports April 17, 2023 Rubén Herzog, Pedro A. M. Mediano, Fernando E. Rosas et al. 51 citations

Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in subjective experience, and provide a unique opportunity to study the neurobiological basis of consciousness. One of the most notable neurophysiological signatures of psychedelics, increased entropy in spontaneous neural activity, is thought to be of...